Table 1.

Available anti-VEGF compounds and their properties [28].

Drug	Type of molecule	Molecular weight	Half-life in posterior segment of eye	Typical drug dosage per injection
Bevacizumab (Avastin™)	Recombinant humanised IgG1 monoclonal antibody inhibitor of VEGF-A	149 kDa	~8 days	1.25 mg in 0.05 ml
Ranibizumab (Lucentis™)	Recombinant humanised IgG1 monoclonal antibody fragment inhibitor of VEGF-A	48 kDa	~5 days	0.5 mg in 0.05 ml
Aflibercept (Eylea™)	Decoy receptor inhibitor of VEGF-A and VEGF-B	115 KDa	~7 days	2.0 mg in 0.05 ml